Mutations in Main Protease of SARS CoV-2 Decreased Boceprevir Affinity

Mutations in Main Protease of SARS CoV-2 Decreased Boceprevir Affinity

Abstract The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global health emergency. The main protease (Mpro) is crucial for the life cycle of coronaviruses. Boceprevir is a potential inhibitor and drug candidate for the Mpro of SARS-C...

Full description

Bibliographic Details
Main Author:	Ekrem Akbulut
Format:	Article
Language:	English
Published:	Instituto de Tecnologia do Paraná (Tecpar) 2022-02-01
Series:	Brazilian Archives of Biology and Technology
Subjects:	boceprevir affinity drug validity main protease mutation SARS-CoV-2
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132021000100434&tlng=en

Similar Items

A suitable drug structure for interaction with SARS‐CoV‐2 main protease between boceprevir, masitinib and rupintrivir; a molecular dynamics study
by: Mehdi Yoosefian, et al.
Published: (2023-09-01)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
by: Karen Anbro Gammeltoft, et al.
Published: (2023-09-01)

Investigation of changes in protein stability and substrate affinity of 3CL-protease of SARS-CoV-2 caused by mutations
by: Ekrem Akbulut
Published: (2022-04-01)

Boceprevir: New possibilities for the antiviral treatment of chronic hepatitis C
by: I G Nikitin, et al.
Published: (2013-02-01)

From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease
by: Matthias Göhl, et al.
Published: (2022-07-01)

The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
by: Midori Kjellin, et al.
Published: (2018-01-01)

Telaprevir or Boceprevir for Hepatitis C treatment: a first survey of pharmacoutilization
by: Maurizio eCapuozzo, et al.
Published: (2013-09-01)

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir
by: Darius Moradpour, et al.
Published: (2012-02-01)

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
by: Borba HHL, et al.
Published: (2017-01-01)

Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies
by: Sakshi Piplani, et al.
Published: (2022-03-01)

Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease
by: Lukas van de Sand, et al.
Published: (2021-04-01)

Identification of Host Cellular Protein Substrates of SARS-COV-2 Main Protease
by: Márió Miczi, et al.
Published: (2020-12-01)

2-Phenoxyacetamide derivatives as SARS-CoV-2 main protease inhibitor: In silico studies
by: Pandu Hariyono, et al.
Published: (2022-01-01)

Insights into the structural properties of SARS-CoV-2 main protease
by: Ibrahim Yagiz Akbayrak, et al.
Published: (2022-01-01)

Molecular Docking of Novel 5-O-benzoylpinostrobin Derivatives as SARS-CoV-2 Main Protease Inhibitors
by: Mohammad Rizki Fadhil Pratama, et al.
Published: (2020-11-01)

Mechanistic Insights into the Inhibition of SARS-CoV-2 Main Protease by Clovamide and Its Derivatives: In Silico Studies
by: Naike Ye, et al.
Published: (2021-09-01)

Inhibitory effect of thymoquinone from Nigella sativa against SARS-CoV-2 main protease. An in-silico study
by: M. T. Khan, et al.
Published: (2022-04-01)

In silico Screening of Potential SARS-CoV-2 Main Protease Inhibitors from Thymus schimperi
by: Mengist HM, et al.
Published: (2023-01-01)

Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
by: Hylemariam Mihiretie Mengist, et al.
Published: (2021-02-01)

Comprehensive Understanding of the Kinetic Behaviors of Main Protease from SARS-CoV-2 and SARS-CoV: New Data and Comparison to Published Parameters
by: Fangya Li, et al.
Published: (2023-06-01)

Structural modification of antineoplastic drug carmofur designed to the inhibition of SARS-CoV-2 main protease: A theoretical investigation
by: Niloofar Hemati, et al.
Published: (2022-01-01)

Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir
by: Alessandro Paciaroni, et al.
Published: (2023-03-01)

Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814
by: Haihai Jiang, et al.
Published: (2023-08-01)

Triterpenic Acid Amides as Potential Inhibitors of the SARS-CoV-2 Main Protease
by: Dmitry S. Baev, et al.
Published: (2022-12-01)

The Main Protease of SARS-CoV-2 as a Target for Phytochemicals against Coronavirus
by: Shaza S. Issa, et al.
Published: (2022-07-01)

Search of Novel Small Molecule Inhibitors for the Main Protease of SARS-CoV-2
by: Wenfa Zhang, et al.
Published: (2023-02-01)

Cotton flower metabolites inhibit SARS‐CoV‐2 main protease
by: Yufang Zhang, et al.
Published: (2022-10-01)

Characterization of host substrates of SARS-CoV-2 main protease
by: Ivonne Melano, et al.
Published: (2023-08-01)

Exploration of Potent Antiviral Phytomedicines from Lauraceae Family Plants against SARS-CoV-2 Main Protease
by: Himashree Bora, et al.
Published: (2022-12-01)

Evaluation of therapeutic potentials of some bioactive compounds in selected African plants targeting main protease (Mpro) in SARS-CoV-2: a molecular docking study
by: Ishola Abeeb Akinwumi, et al.
Published: (2023-12-01)

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
by: Chunlong Ma, et al.
Published: (2022-04-01)

Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs
by: Lena Parigger, et al.
Published: (2022-12-01)

Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug
by: Camilla Isgrò, et al.
Published: (2021-01-01)

A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease
by: Eslam B. Elkaeed, et al.
Published: (2022-07-01)

Crystal structures of main proteases of SARS-CoV-2 variants bound to a benzothiazole-based inhibitor
by: Luo Jiqing, et al.
Published: (2023-06-01)

First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder
by: Nawal Al Nahdi, et al.
Published: (2013-01-01)

Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease
by: János András Mótyán, et al.
Published: (2022-03-01)

Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design
by: Wei Yu, et al.
Published: (2021-12-01)

Antiviral drug discovery by targeting the SARS-CoV-2 polyprotein processing by inhibition of the main protease
by: Mahmoud Kandeel, et al.
Published: (2022-02-01)

Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188
by: Gordon J. Lockbaum, et al.
Published: (2021-01-01)